October 9, 2024 11:37 AM EDT
News Briefing

Cri­net­ics’ $500M of­fer­ing; Boehringer inks deal with macro­cy­cles biotech

ENDPOINTS

Plus, news about In­hibikase, Bio-Thera, Richter, In­no­Care and Schol­ar Rock:

Cri­net­ics prices $500M of­fer­ing: The San Diego biotech up­sized the of­fer­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lex­i­con ends com­mer­cial work to fo­cus on R&D

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times